Page last updated: 2024-10-29

irsogladine and Angiogenesis, Pathologic

irsogladine has been researched along with Angiogenesis, Pathologic in 5 studies

irsogladine: RN given refers to parent cpd; MN 1695 refers to maleate salt

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's5 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Sato, Y2
Morimoto, A1
Kiue, A1
Okamura, K1
Hamanaka, R1
Kohno, K1
Kuwano, M4
Sakata, T1
Ono, M3
Kawahara, N1
Goto, D1
Wakabayashi, Y1
Ushiro, S1
Yoshida, S1
Izumi, H1
Ren, CJ1
Ueda, F1
Roses, DF1
Harris, MN1
Mignatti, P1
Rifkin, DB1
Shapiro, RL1

Reviews

2 reviews available for irsogladine and Angiogenesis, Pathologic

ArticleYear
[Development of anti tumor agents targeting angiogenesis].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:2

    Topics: Antineoplastic Agents; Clinical Trials as Topic; Cyclohexanes; Drug Screening Assays, Antitumor; Enz

1997
[Angiogenesis and its inhibitors].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:11

    Topics: Animals; Antineoplastic Agents; Collagen; Endostatins; Endothelium, Vascular; Growth Inhibitors; Hum

1997

Other Studies

3 other studies available for irsogladine and Angiogenesis, Pathologic

ArticleYear
Irsogladine is a potent inhibitor of angiogenesis.
    FEBS letters, 1993, May-10, Volume: 322, Issue:2

    Topics: Animals; Cells, Cultured; Endothelium, Vascular; Enzyme Induction; Humans; Mice; Neovascularization,

1993
Inhibition of tumor growth and neovascularization by an anti-gastric ulcer agent, irsogladine.
    Cancer research, 1996, Apr-01, Volume: 56, Issue:7

    Topics: Animals; Anti-Ulcer Agents; Antineoplastic Agents; Cell Line; Humans; Male; Mice; Mice, Inbred BALB

1996
Irsogladine maleate inhibits angiogenesis in wild-type and plasminogen activator-deficient mice.
    The Journal of surgical research, 1998, Jul-01, Volume: 77, Issue:2

    Topics: Animals; Antineoplastic Agents; Cornea; Dose-Response Relationship, Drug; Fibroblast Growth Factor 2

1998